Thrombosis recanalization by paeoniflorin through the upregulation of urokinase-type plasminogen activator via the MAPK signaling pathway

Molecular Medicine Reports

Volumn 13, Issue 6, 2016, Pages 4593-4598

  Ye, Songshan ^a   Mao, Bingyu ^a   Yang, Lei ^a   Fu, Weiyun ^a   Hou, Junran ^a  

^a NANYANG INSTITUTE OF TECHNOLOGY   (China)

Author keywords

Mitogen acitvated protein kinase; Paeoniflorin; Plasminogen activator urokinase; Prothrombotic states

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; 6 OXOPROSTAGLANDIN F1 ALPHA; ACETYLSALICYLIC ACID; ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; D DIMER; FIBRINOGEN; FIBRONECTIN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; PAEONIFLORIN; THROMBOXANE B2; UROKINASE; GLUCOSIDE; STRESS ACTIVATED PROTEIN KINASE; TERPENE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; ENZYME INDUCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME PHOSPHORYLATION; EXPERIMENTAL THROMBOSIS; HUMAN; HUMAN CELL; MALE; METHYL THIAZOLYL TETRAZOLIUM ASSAY; NONHUMAN; PROTEIN EXPRESSION; RAT; RECANALIZATION; SIGNAL TRANSDUCTION; UMBILICAL VEIN ENDOTHELIAL CELL; WESTERN BLOTTING; ANIMAL; BLOOD CLOTTING; CELL PROLIFERATION; CELL SURVIVAL; CHEMISTRY; DISEASE MODEL; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MOUSE; PATHOLOGY; PHOSPHORYLATION; THROMBOSIS;

ANIMALS; BLOOD COAGULATION; CELL PROLIFERATION; CELL SURVIVAL; DISEASE MODELS, ANIMAL; GENE EXPRESSION REGULATION; GLUCOSIDES; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; JNK MITOGEN-ACTIVATED PROTEIN KINASES; MALE; MAP KINASE SIGNALING SYSTEM; MICE; MONOTERPENES; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; THROMBOSIS; UROKINASE-TYPE PLASMINOGEN ACTIVATOR;

EID: 84966480845     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2016.5146     Document Type: Article

References (28)

1. Italiano JE, Patel-Hett S and Hartwig JH: Mechanics of proplatelet elaboration. J Thromb Haemost 5 (Suppl 1): S18-S23, 2007.
2. Bender M, Eckly A, Hartwig JH, Elvers M, Pleines I, Gupta S, Krohne G, Jeanclos E, Gohla A, Gurniak C, et al: ADF/n-cofilin-dependent actin turnover determines platelet formation and sizing. Blood 116: 1767-1775, 2010.
3. Ruggeri ZM: Platelets in atherothrombosis. Nature Med 8: 1227-1234, 2002.
4. Stoll G, Kleinschnitz C and Nieswandt B: Molecular mechanisms of thrombus formation in ischemic stroke: Novel insights and targets for treatment. Blood 112: 3555-3562, 2008.
5. Schrör K: Antiplatelet drugs. A comparative review. Drugs 50: 7-28, 1995.
6. Ni H and Freedman J: Platelets in hemostasis and thrombosis: Role of integrins and their ligands. Transfus Apher Sci 28: 257-264, 2003.
7. Barrett NE, Holbrook L, Jones S, Kaiser WJ, Moraes LA, Rana R, Sage T, Stanley RG, Tucker KL, Wright B and Gibbins JM: Future innovations in anti-platelet therapies. Br J Pharmacol 154: 918-939, 2008.
8. Bird JE, Giancarli MR, Allegretto N, Barbera F, Wong P, Schumacher WA, Ogletree ML and Seiffert D: Prediction of the therapeutic index of marketed anti-coagulants and anti-platelet agents by guinea pig models of thrombosis and hemostasis. Thromb Res 123: 146-158, 2008.
9. Northeast AD, Soo KS, Bobrow LG, Gaffney PJ and Burnand KG: The tissue plasminogen activator and urokinase response in vivo during natural resolution of venous thrombus. J Vasc Surg 22: 573-579, 1995.
10. Singh I, Burnand KG, Collins M, Luttun A, Collen D, Boelhouwer B and Smith A: Failure of thrombus to resolve in urokinase-type plasminogen activator gene-knockout mice: Rescue by normal bone marrow-derived cells. Circulation 107: 869-875, 2003.
11. Gossage JA, Humphries J, Modarai B, Burnand KG and Smith A: Adenoviral urokinase-type plasminogen activator (uPA) gene transfer enhances venous thrombus resolution. J Vasc Surg 44: 1085-1090, 2006.
12. Aguirre Ghiso JA, Alonso DF, Farías EF, Gomez DE and Bal de Kier Joffè E: Deregulation of the signaling pathways controlling urokinase production. Its relationship with the invasive phenotype. Eur J Biochem 263: 295-304, 1999.
13. Blasi F and Carmeliet P: uPAR: A versatile signalling orchestrator. Nat Rev Mol Cell Biol 3: 932-943, 2002.
14. Lee KH, Hyun MS and Kim JR: Growth factor-dependent activation of the MAPK pathway in human pancreatic cancer: MEK/ERK and p38 MAP kinase interaction in uPA synthesis. Clin Exp Metastasis 20: 499-505, 2003.
15. Liu SQ, Huang JA, Qin MB, Su YJ, Lai MY, Jiang HX and Tang GD: Sphingosine kinase 1 enhances colon cancer cell proliferation and invasion by upregulating the production of MMP-2/9 and uPA via MAPK pathways. Int J Colorectal Dis 27: 1569-1578, 2012.
16. Benasciutti E, Pagès G, Kenzior O, Folk W, Blasi F and Crippa MP: MAPK and JNK transduction pathways can phosphorylate Sp1 to activate the uPA minimal promoter element and endogenous gene transcription. Blood 104: 256-262, 2004.
17. Nizamutdinova IT, Jin YC, Kim JS, Yean MH, Kang SS, Kim YS, Lee JH, Seo HG, Kim HJ and Chang KC: Paeonol and paeoniflorin, the main active principles of Paeonia albiflora, protect the heart from myocardial ischemia/reperfusion injury in rats. Planta medica 74: 14-18, 2008.
18. Guo RB, Wang GF, Zhao AP, Gu J, Sun XL and Hu G: Paeoniflorin protects against ischemia-induced brain damages in rats via inhibiting MAPKs/NF-κB-mediated inflammatory responses. PLoS One 7: e49701, 2012.
19. National Research Council: Guide for the Care and Use of Laboratory Animals. 8th edition. National Academies Press, Washington, D.C., 1996.
20. Miner J and Hoffhines A: The discovery of aspirin's antithrombotic effects. Tex Heart Inst J 34: 179-186, 2007.
21. Lijnen HR: Matrix metalloproteinases and cellular fibrinolytic activity. Biochemistry (Mosc) 67: 92-98, 2002.
22. Burnand KG, Gaffney PJ, McGuinness CL, Humphries J, Quarmby JW and Smith A: The role of the monocyte in the generation and dissolution of arterial and venous thrombi. Cardiovasc Surg 6: 119-125, 1998.
23. Ye J, Duan H, Yang X, Yan W and Zheng X: Anti-thrombosis effect of paeoniflorin: Evaluated in a photochemical reaction thrombosis model in vivo. Planta Med 67: 766-767, 2001.
24. Yoshida A, Nakao S, Kobayashi M and Kobayashi H: Flow-mediated vasodilation and plasma fibronectin levels in preeclampsia. Hypertension 36: 400-404, 2000.
25. Pulkkinen MO, Lehto M, Jalkanen M and Näntö-Salonen K: Collagen types and fibronectin in the uterine muscle of normal and hypertensive pregnant patients. Am J Obstet Gynecol 149: 711-717, 1984.
26. Lowe GD and Rumley A: Use of fibrinogen and fibrin D-dimer in prediction of arterial thrombotic events. Thromb Haemost 82: 667-672, 1999.
27. Bowen RS, Zhang Y, Gu Y, Lewis DF and Wang Y: Increased phospholipase A2 and thromboxane but not prostacyclin production by placental trophoblast cells from normal and preeclamptic pregnancies cultured under hypoxia condition. Placenta 26: 402-409, 2005.
28. Zhao S, Gu Y, Lewis DF and Wang Y: Predominant basal directional release of thromboxane, but not prostacyclin, by placental trophoblasts from normal and preeclamptic pregnancies. Placenta 29: 81-88, 2008.